Delta‐like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials

Delta‐like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials

Abstract Delta‐like ligand 4 (DLL‐4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL‐4 is associated with development of pulmonary hypertension, in the absence of left ventricular...

Full description

Saved in:
Bibliographic Details
Main Authors: Casandra E. Besse, Nolan M. Winicki, Cristian Puerta, Moises Hernandez, Jason X.‐J. Yuan, Patricia A. Thistlethwaite
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Pulmonary Circulation
Subjects:
adverse effects
clinical trials
pulmonary hypertension
Online Access:https://doi.org/10.1002/pul2.12450
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/pul2.12450

Similar Items